Hence, in addition to evidence from the genetic studies mentioned above, CXCL12 has been associated with atherogenic dyslipidaemia, pro-thrombotic activity, poorer cardiovascular outcomes and progression of atherosclerosis (after endothelial injury), making it a potential biomarker and therapeutic target. The gene discussed is CXCL12; the disease is atherosclerosis.